Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
2
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.
Abstract
Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.
참고문헌 (59)
- Holtmann MH, "From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowel disease", Adv Exp Med Biol, 579, pp.227~242 (2006)
- Molodecky NA, "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review", Gastroenterology, 142, pp.46~54.e42 (2012)
- Gabbani T, "The genetic burden of inflammatory bowel diseases: implications for the clinic", Expert Rev Gastroenterol Hepatol, 10, pp.1109~1117 (2016)
- Vogelaar L, "The impact of biologics on health-related quality of life in patients with inflammatory bowel disease", Clin Exp Gastroenterol, 2, pp.101~109 (2009)
- Bernstein CN, "Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn’s disease", Gut, 61, pp.622~629 (2012)
- Barker N, "Identification of stem cells in small intestine and colon by marker gene Lgr5", Nature, 449, pp.1003~1007 (2007)
- Fasano A, "Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases", Nat Clin Pract Gastroenterol Hepatol, 2, pp.416~422 (2005)
- Khor B, "Genetics and pathogenesis of inflammatory bowel disease", Nature, 474, pp.307~317 (2011)
- Prager M, "The JAK2 variant rs10758669 in Crohn’s disease: altering the intestinal barrier as one mechanism of action", Int J Colorectal Dis, 27, pp.565~573 (2012)
- Stoll M, "Genetic variation in DLG5 is associated with inflammatory bowel disease", Nat Genet, 36, pp.476~480 (2004)
- Atreya R, "IBD pathogenesis in 2014: molecular pathways controlling barrier function in IBD", Nat Rev Gastroenterol Hepatol, 12, pp.67~68 (2015)
- Günther C, "Regulation and pathophysiological role of epithelial turnover in the gut", Semin Cell Dev Biol, 35, pp.40~50 (2014)
- Becker C, "Complex roles of caspases in the pathogenesis of inflammatory bowel disease", Gastroenterology, 144, pp.283~293 (2013)
- Coskun M, "The role of CDX2 in inflammatory bowel disease", Dan Med J, 61, pp.B4820~ (2014)
- Dave M, "Immunology of inflammatory bowel disease and molecular targets for biologics", Gastroenterol Clin North Am, 43, pp.405~424 (2014)
- Cristofaro P, "Role of Toll-like receptors in infection and immunity: clinical implications", Drugs, 66, pp.15~29 (2006)
- Li J, "Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases", Pharmacol Ther, 138, pp.441~451 (2013)
- Pochini L, "OCTN cation transporters in health and disease: role as drug targets and assay development", J Biomol Screen, 18, pp.851~867 (2013)
- Ayabe T, "Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria", Nat Immunol, 1, pp.113~118 (2000)
- Neurath MF, "New targets for mucosal healing and therapy in inflammatory bowel diseases", Mucosal Immunol, 7, pp.6~19 (2014)
- Fuss IJ, "Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis", J Clin Invest, 113, pp.1490~1497 (2004)
- Vaishnava S, "Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface", Proc Natl Acad Sci U S A, 105, pp.20858~20863 (2008)
- Wehkamp J, "NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression", Gut, 53, pp.1658~1664 (2004)
- Lala S, "Crohn’s disease and the NOD2 gene: a role for paneth cells", Gastroenterology, 125, pp.47~57 (2003)
- Boya P, "Emerging regulation and functions of autophagy", Nat Cell Biol, 15, pp.713~720 (2013)
- Rioux JD, "Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis", Nat Genet, 39, pp.596~604 (2007)
- McCarroll SA, "Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn’s disease", Nat Genet, 40, pp.1107~1112 (2008)
- Neurath MF, "Cytokines in inflammatory bowel disease", Nat Rev Immunol, 14, pp.329~342 (2014)
- Cordero Ruiz P, "Efficacy of adalimumab in patients with Crohn’s disease and failure to infliximab therapy: a clinical series", Rev Esp Enferm Dig, 103, pp.294~298 (2011)
- Corleto VD, "IL-1beta-511 and IL- 1RN*2 polymorphisms in inflammatory bowel disease: an Italian population study and meta-analysis of European studies", Dig Liver Dis, 42, pp.179~184 (2010)
- Atreya R, "Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages", Gastroenterology, 141, pp.2026~2038 (2011)
- Kamada N, "Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23", IFN-gamma axis, 2008, pp.118, 2269~2280
- Zenewicz LA, "CD4 T-cell differentiation and inflammatory bowel disease", Trends Mol Med, 15, pp.199~207 (2009)
- Isaacs KL, "State of the art: IBD therapy and clinical trials in IBD", Inflamm Bowel Dis, 11(Suppl 1), pp.S3~S12 (2005)
- Nishimura M, "Chemokines as novel therapeutic targets for inflammatory bowel disease", Ann N Y Acad Sci, 1173, pp.350~356 (2009)
- Zundler S, "Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing", Clin Exp Rheumatol, 33(4 Suppl 92), pp.S19~S28 (2015)
- Coombes JL, "A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism", J Exp Med, 204, pp.1757~1764 (2007)
- Kelsall B, "Interleukin-10 in inflammatory bowel disease", N Engl J Med, 361, pp.2091~2093 (2009)
- McLean MH, "Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy", Inflamm Bowel Dis, 20, pp.389~397 (2014)
- Mosli MH, "T-cell trafficking and antiadhesion strategies in inflammatory bowel disease: current and future prospects", Drugs, 74, pp.297~311 (2014)
- Johansson-Lindbom B, "Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing", J Exp Med, 202, pp.1063~1073 (2005)
- Mora JR, "Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells", Nature, 424, pp.88~93 (2003)
- Berlin C, "Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAd- CAM-1", Cell, 74, pp.185~195 (1993)
- Briskin M, "Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue", Am J Pathol, 151, pp.97~110 (1997)
- Vermeire S, "A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis (UC): results of the TURANDOT study", J Crohns Colitis, 148(4 Suppl 1), pp.S1193~ (2015)
- Vermeire S, "Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial", Lancet, 384, pp.309~318 (2014)
- Ericsson A, "CCL25", CCR9 promotes the induction and function of CD103 on intestinal intraepithelial lymphocytes, 2004, pp.34, 2720~2729
- D’Alessio S, "Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease", Curr Opin Gastroenterol, 29, pp.608~613 (2013)
- Biasi F, "Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets", Antioxid Redox Signal, 19, pp.1711~1747 (2013)
- Tokuhira N, "PI3K", AKT, Int J Mol Med, pp.2015, 35[DOI]
- Schottelius AJ, "A role for transcription factor NF-kappa B in intestinal inflammation", Int J Colorectal Dis, 14, pp.18~28 (1999)
- Scaldaferri F, "Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives", Mediators Inflamm, 2013, pp.391473~ (2013)
- Malik T, "Inflammatory bowel diseases: emerging therapies and promising molecular targets", Front Biosci (Schol Ed), 4, pp.1172~1189 (2012)
- Leppkes M, "Immune deficiency vs. immune excess in inflammatory bowel diseases- STAT3 as a rheo-STAT of intestinal homeostasis", J Leukoc Biol, 99, pp.57~66 (2016)
- Panaccione R, "Advances in medical therapy of inflammatory bowel disease", Curr Opin Pharmacol, 5, pp.566~572 (2005)
- Cole AT, "Treatment of inflammatory bowel disease from now to the millennium", Baillieres Clin Gastroenterol, 8, pp.351~379 (1994)
- Zundler S, "How will new and future therapies change our treatment of IBD", Expert Rev Clin Immunol, 12, pp.233~236 (2016)
- Leiman DA, "Therapy of inflammatory bowel disease: what to expect in the next decade", Curr Opin Gastroenterol, 30, pp.385~390 (2014)
- Bene L, "Cellular and molecular mechanisms in the two major forms of inflammatory bowel disease", Pathol Oncol Res, 17, pp.463~472 (2011)